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Heart failure  with  preserved  ejection  fraction  (HFpEF)  is  a  growing  public  health  problem
[1—3].  Indeed,  studies  of  patients  with  heart  failure  (HF),  such  as  Acute  Decompensated
Heart  Failure  National  Registry  (ADHERE)  [4],  Organized  Program  to  Initiate  Lifesaving
Treatment  in  Hospitalized  Patients  with  Heart  Failure  (OPTIMIZE-HF)  [5],  EuroHeart  Fail-
ure  Survey  II  (EHFS-II)  [6]  and  Épidémiologie  et  Traitement  de  l’Insufﬁsance  Cardiaque  dans
la  Somme  (ETICS)  [1], indicate  that  34  to  55%  of  patients  hospitalized  for  HF  have  preserved
left  ventricular  (LV)  ejection  fraction  (EF).  Clinical  registries  have  consistently  highlighted
the  clinical  proﬁle  of  patients  with  HFpEF;  these  individuals  are  predominantly  elderly
women  with  a  high  prevalence  of  hypertension,  atrial  ﬁbrillation,  diabetes  mellitus  and
obesity  with  metabolic  syndrome  [1—3]. The  prevalence  of  HFpEF  has  increased  over  the
past  three  decades,  in  parallel  with  the  ageing  of  the  population  and  the  increasing  preva-préservée  ;
Dysfonction
diastolique
lence  of  hypertension,  atrial  ﬁbrillation  and  diabetes  [7].  In  contrast,  the  prevalence  of
both  coronary  artery  disease  (CAD)  and  heart  failure  with  reduced  ejection  fraction  (HFrEF)
has  remained  stable  [7].  Moreover,  over  the  past  three  decades,  survival  has  improved  for
HFrEF  but  not  for  HFpEF  [7].
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According  to  current  guidelines  [8],  the  diagnosis  of
FpEF  requires  the  presence  of  the  following  conditions:
signs  or  symptoms  of  HF;
normal  or  mildly  abnormal  systolic  LV  function  (LVEF  >  50%
and  a  LV  end-diastolic  volume  index  ≤  97  mL/m2);
evidence  of  diastolic  LV  dysfunction  by  echocardiography
and/or  haemodynamic  invasive  evaluation.
Unfortunately,  these  diagnostic  criteria  are  often  not
ppropriately  applied  to  patients  enrolled  in  clinical  trials
r  registries,  leading  to  great  heterogeneity  in  the  study
opulations.  Thus,  a  review  of  21  HFpEF  studies  found  that
he  cut-off  value  for  preserved  EF  (pEF)  ranged  from  35%  to
0%,  with  only  eight  series  using  the  recommended  value  of
0%  [9].  Use  of  common  diagnostic  criteria  in  future  clinical
esearch  is  therefore  imperative.
Echocardiography  —  the  cornerstone  for  HFpEF  diagno-
is  [10]  —  remains  insufﬁciently  used  in  elderly  patients
dmitted  to  hospital  for  HF  [11]  despite  the  fact  that
arly  use  of  this  technique  appears  associated  with  more
ntensive  drug  therapy  and  improved  outcome  in  this  pop-
lation  [11].  The  echocardiographic  features  of  HFpEF
nclude  increased  LV  mass  and/or  concentric  LV  remod-
lling,  decreased  LV  longitudinal  deformation,  increased  LV
lling  pressures,  an  enlarged  left  atrium,  the  presence  of
ild-to-moderate  functional  mitral  regurgitation  [12]  and
ulmonary  artery  hypertension  [13,14].  The  reestablishment
f  a  compensated  state  in  HFpEF  is  associated  with  a  sig-
iﬁcant  reduction  in  E/e’  ratio,  mitral  regurgitation  and
ulmonary  pressure;  this  emphasizes  the  value  of  repeat-
ng  an  echocardiographic  examination  after  the  initiation  of
ppropriate  therapy  [15].
Patients  with  HFpEF  have  a  poor  prognosis  in  general
nd  notably  display  a  signiﬁcantly  lower  5-year  survival  rate
han  age-  and  gender-matched  controls  from  the  general
opulation  (43%  and  72%,  respectively)  [1].  One-year  mor-
ality  rates  in  patients  with  HFpEF  are  dramatically  lower
n  randomized  clinical  trials  (4—5%)  [16—19]  than  in  reg-
stries  (22—29%)  because  patients  are  frequently  enrolled
n  the  registries  after  hospitalization  for  HF  and  are  there-
ore  sicker  than  those  enrolled  in  randomized  trials  [1—3].
hile  some  registries  have  reported  similar  prognosis  for
FpEF  and  HFrEF  [2,8],  randomized  trials  and  a  meta-
nalysis  have  reported  better  outcomes  for  HFpEF  [20].  This
pparent  discrepancy  may  be  explained  by  interstudy  dif-
erences  in  the  patient  populations,  aetiologies  and  criteria
sed  to  diagnose  HFpEF.  The  wide  variability  of  CAD  preva-
ence  in  HFpEF  studies  and  the  rarely  documented  functional
igniﬁcance  of  coronary  lesions  also  emphasize  these  dif-
erences  between  study  populations.  Whether  obstructive
AD  presents  a  potential  therapeutic  target  for  reducing
he  high  rates  of  death  and  hospitalization  in  a  subset  of
atients  with  HFpEF  certainly  deserves  further  investiga-
ions.  On  the  other  hand,  comorbidities  such  as  diabetes,
moking,  chronic  kidney  failure  and  anaemia  are  frequent
nd  well  documented  predictors  of  death  in  patients  with
FpEF  [21—24].  This  high  comorbidity  burden  could  explain
hy  outcomes  in  recent  trials  of  pharmacological  treat-
ents  of  HF  were  consistently  found  to  be  neutral  in  HFpEF
25].  Accordingly,  the  results  of  a  community-based  study
uggested  that  the  frequency  of  non-cardiovascular  deaths
mong  patients  with  HFpEF  is  high  [21].  In  contrast,  a
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rospective  registry  found  that  5-year  cardiovascular  mor-
ality  was  similar  in  HFpEF  and  HFrEF  groups  [1]. Although
he  debate  on  whether  HFpEF  has  a  better  or  a  similar  prog-
osis  to  HFrEF  is  still  ongoing,  we  do  not  consider  this  issue
o  be  the  most  important.  Given  that  HFpEF  clearly  has  a
ocumented  poor  prognosis,  the  main  challenges  in  order  to
dentify  effective  therapies  and  improve  outcomes  are  to:
better  understand  the  complex  pathophysiological  fea-
tures  of  this  frequent  condition;
deﬁne  subsets  of  patients  according  to  aetiology;
document  the  major  causes  of  death.
Despite  the  presence  of  a  large  body  of  published  data,
t  must  be  borne  in  mind  that  the  pathophysiology  of  HFpEF
s  not  fully  understood.  The  involvement  of  many  different
echanisms  has  been  hypothesized,  such  as:
increased  myocardial  stiffness  with  restrictive  abnormal-
ities  of  the  left  ventricle;
hypertension-induced  LV  hypertrophy  (resulting  in  LV  dia-
stolic  dysfunction);
impaired  ventriculovascular  coupling;
combined  vascular  stiffening  [26—28].
Peripheral  changes  may  also  have  a  major  impact.  Periph-
ral  endothelial  dysfunction  in  patients  with  HFpEF  seems  to
e  correlated  with  a  poor  outcome  and  future  cardiovascu-
ar  events  [29]. Furthermore,  patients  with  HFpEF  exhibit
ntrarenal  vascular  haemodynamic  alterations,  the  severity
f  which  correlate  with  a  poor  outcome  [30].  These  ﬁnd-
ngs  prompted  researchers  to  suggest  that  congestion  can
lso  result  from  extracardiac  abnormalities  (such  as  water
nd  salt  retention  by  the  kidney).  An  increase  in  LV  ﬁlling
ressure  could  be  the  harbinger  of  water  and  salt  retention
ather  than  the  primary  cause  of  congestion  [28].  Actually,
here  are  many  remaining  unanswered  questions  concern-
ng  the  physiopathology  of  HFpEF,  as  Burkhoff  et  al.  already
ointed  out  in  a thought-provoking  editorial  10  years  ago
ntitled  ‘Have  we  failed  [to  ﬁnd  to  a  single  effective  treat-
ent  for  HFpEF]  because  diastolic  dysfunction  is  too  difﬁcult
o  understand  or  manage,  or  is  it  because  HFpEF  has  nothing
o  do  with  diastolic  dysfunction  at  all?’  [31].
Cardiac  resynchronization  therapy  is  currently  recom-
ended  as  a  means  of  relieving  symptoms,  boosting  LV
unction  and  improving  the  prognosis  in  patients  with
oderate-to-severe  HF,  LV  systolic  dysfunction  and  pro-
onged  QRS  duration  [32].  In  this  quest  for  the  ‘holy  grail’
i.e.  therapy  that  effectively  improves  outcomes  in  HFpEF),
 number  of  landmark  studies  have  reported  mechanical
yssynchrony  in  patients  with  HFpEF.  The  KaRen  study  is
 multicentre,  international,  prospective  study  designed  to
ssess  the  prevalence  of  mechanical  dyssynchrony  in  HFpEF
33]. In  the  present  issue  of  the  Archives  of  Cardiovascular
iseases,  Donal  et  al.  report  on  the  study  population’s  base-
ine  clinical  proﬁle  [34]. The  results  are  in  agreement  with
he  published  literature:  a  high  proportion  of  hypertensive
omen  with  a  high  comorbidity  burden.  The  inclusion  crite-
ia  were  generally  in  line  with  current  guidelines,  although
he  LVEF  threshold  was  45%.  However,  it  must  be  remem-
ered  that  the  test  —  retest  variability  of  Simpson’s  biplane
echnique  can  be  as  high  as  6  ±  9%  in  stable  patients,  indi-
ating  that  use  of  a  cut-off  value  of  45%  (rather  than  50%)
ay  not  necessarily  weaken  future  results  from  the  KaRen
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study  [35].  The  echocardiographic  characteristics  of  the
patient  population  are  highly  consistent  with  those  of  previ-
ously  publications:  LV  hypertrophy,  an  enlarged  left  atrium
and  poor  LV  longitudinal  and  diastolic  function.  Importantly,
electrical  dyssynchrony  was  very  uncommon  in  patients  with
HFpEF,  since  only  15.7%  displayed  lengthening  of  the  QRS
complex,  3.6%  had  left  bundle  branch  block  and  7.3%  had
right  ventricle  pacing.  Although  mechanical  dyssynchrony
was  not  frequently  observed  in  the  study  population,  a broad
range  of  dyssynchrony  parameters  was  found.  For  exam-
ple,  the  tissue  Doppler  imaging  time  difference  between
the  septal  and  lateral  sides  of  the  mitral  annulus  ranged
from  —94  ms  to  301  ms.  Similar  results  were  found  for  strain
data,  indicating  that  marked  mechanical  dyssynchrony  can
be  observed  in  some  patients  with  HFpEF.  Whether  this
mechanical  dyssynchrony  is  linked  to  the  clinical  outcome
and  could  be  a  speciﬁc  therapeutic  target  is  an  important
question  that  will  require  further  analysis  of  the  KaRen  reg-
istry  data.  Because  the  KaRen  study  population  appears  to
be  typical  of  HFpEF  and  has  consistent  clinical  and  echocar-
diographic  ﬁndings,  these  data  appear  to  form  a  solid  basis
for  addressing  the  study’s  primary  objective:  assessment  of
the  role  of  dyssynchrony  in  the  pathophysiology  of  HFpEF
[36].
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